Physician profile
Gregory W Edens
NPI 1952365173
$5,073.37
in general payments reported to CMS, 2019-2025
41 companies · $39.22 in 2025
The $39.22 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,498 · 2020: $663 · 2021: $960 · 2022: $1,181 · 2023: $718 · 2024: $14.28 · 2025: $39.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $771.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $662.50 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Abbvie INC. | $468.31 | 2019-2023 | Vraylar, Ubrelvy |
| Pfizer INC. | $466.71 | 2019-2024 | |
| Lilly USA, LLC | $441.02 | 2019-2023 | Jardiance, Mounjaro, Trulicity |
| Astrazeneca Pharmaceuticals LP | $339.21 | 2019-2023 | Farxiga, Breztri |
| Astellas Pharma US INC | $256.23 | 2019-2022 | |
| Glaxosmithkline, LLC. | $241.89 | 2019-2023 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.65 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Merck Sharp & Dohme LLC | $198.38 | 2019-2023 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $172.57 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $168.87 | 2019-2022 | |
| Amgen INC. | $142.20 | 2019-2023 | Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $126.88 | 2019-2021 | |
| Amarin Pharma, INC. | $118.83 | 2019-2021 | |
| Allergan, INC. | $95.07 | 2019-2020 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Edens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.